12:09pm ET
Investing
Insider Buying at These Biotechs Is Huge
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
Companies
/Healthcare
Adicet Bio Inc
$7.14
▲ $0.31 (+4.54%) today
Markets closed · 3:36am ET
Fundamentals
Market Cap
$63.9M
EPS (TTM)
$-11.33
52-Week Range
$6 – $17
Street Target
$34.83
About Adicet Bio
Adicet Bio Inc is a pioneering biotechnology firm based in Boston, Massachusetts, focused on developing innovative cancer treatments. It specializes in creating allogeneic gamma delta T cell therapies, a cutting-edge approach that aims to improve the body's immune response against tumors. The company's flagship product, ADI-001, is currently undergoing clinical trials for non-Hodgkin’s lymphoma. Additionally, Adicet Bio is working on other promising therapies, including ADI-002 for solid tumors and ADI-925, which targets tumor stress ligands for enhanced cancer targeting.
